Cargando…

Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes

BACKGROUND: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented in current literature with long term oncological follow up. METHODS: This is a single ins...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Taji, Omar, Al-Mitwalli, Abdullah, Malik, Farhan, Agarwal, Samita, Gogbashian, Andrew, Hughes, Rob, Vasdev, Nikhil, Sharma, Anand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261409/
https://www.ncbi.nlm.nih.gov/pubmed/34295729
http://dx.doi.org/10.21037/tau-20-955
_version_ 1783719006157406208
author El-Taji, Omar
Al-Mitwalli, Abdullah
Malik, Farhan
Agarwal, Samita
Gogbashian, Andrew
Hughes, Rob
Vasdev, Nikhil
Sharma, Anand
author_facet El-Taji, Omar
Al-Mitwalli, Abdullah
Malik, Farhan
Agarwal, Samita
Gogbashian, Andrew
Hughes, Rob
Vasdev, Nikhil
Sharma, Anand
author_sort El-Taji, Omar
collection PubMed
description BACKGROUND: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented in current literature with long term oncological follow up. METHODS: This is a single institutional, retrospective cohort study of patients with a histological diagnosis of a secondary bladder neoplasm from January 2007 to December 2017 (n=40). Prognostic variables examined included age at diagnosis, histology, disease free survival and treatment. Kaplan-Meier analysis was used to calculate survival. We used multiple regression analysis to identify the most significant treatments for each population group in terms of their survival. RESULTS: Twenty-one patients were male (53%) with a median age of 68 and 19 were female (47%) with a median age of 64. The most common secondary neoplasms and their median survival were prostate [12 patients (30%), 446 days], colorectal [9 patients (23%), 403 days], ovarian [5 patients (13%), 369 days], cervical [4 patients (10%), 148 days], breast [3 patients (8%), 241 days], lymphoma [3 patients (8%), 145 days], gastric [2 patients (5%), 66 days], and renal [2 patients (5%), 854 days]. Those receiving treatment following a secondary diagnosis demonstrated statistical significance in survival for colorectal (surgery P=0.013), prostate (radiotherapy P=0.0012 and hormonal therapy P=0.004) and ovarian cancer (chemotherapy P=0.00002). CONCLUSIONS: Prognosis and treatment depends upon the primary neoplasm. There is some survival benefit in well selected patients receiving treatment following a diagnosis of a bladder secondary.
format Online
Article
Text
id pubmed-8261409
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-82614092021-07-21 Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes El-Taji, Omar Al-Mitwalli, Abdullah Malik, Farhan Agarwal, Samita Gogbashian, Andrew Hughes, Rob Vasdev, Nikhil Sharma, Anand Transl Androl Urol Original Article BACKGROUND: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however there is limited literature reporting management and survival. This is the largest single centre series presented in current literature with long term oncological follow up. METHODS: This is a single institutional, retrospective cohort study of patients with a histological diagnosis of a secondary bladder neoplasm from January 2007 to December 2017 (n=40). Prognostic variables examined included age at diagnosis, histology, disease free survival and treatment. Kaplan-Meier analysis was used to calculate survival. We used multiple regression analysis to identify the most significant treatments for each population group in terms of their survival. RESULTS: Twenty-one patients were male (53%) with a median age of 68 and 19 were female (47%) with a median age of 64. The most common secondary neoplasms and their median survival were prostate [12 patients (30%), 446 days], colorectal [9 patients (23%), 403 days], ovarian [5 patients (13%), 369 days], cervical [4 patients (10%), 148 days], breast [3 patients (8%), 241 days], lymphoma [3 patients (8%), 145 days], gastric [2 patients (5%), 66 days], and renal [2 patients (5%), 854 days]. Those receiving treatment following a secondary diagnosis demonstrated statistical significance in survival for colorectal (surgery P=0.013), prostate (radiotherapy P=0.0012 and hormonal therapy P=0.004) and ovarian cancer (chemotherapy P=0.00002). CONCLUSIONS: Prognosis and treatment depends upon the primary neoplasm. There is some survival benefit in well selected patients receiving treatment following a diagnosis of a bladder secondary. AME Publishing Company 2021-06 /pmc/articles/PMC8261409/ /pubmed/34295729 http://dx.doi.org/10.21037/tau-20-955 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
El-Taji, Omar
Al-Mitwalli, Abdullah
Malik, Farhan
Agarwal, Samita
Gogbashian, Andrew
Hughes, Rob
Vasdev, Nikhil
Sharma, Anand
Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
title Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
title_full Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
title_fullStr Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
title_full_unstemmed Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
title_short Secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
title_sort secondary neoplasms of the urinary bladder-clinical management and oncological outcomes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261409/
https://www.ncbi.nlm.nih.gov/pubmed/34295729
http://dx.doi.org/10.21037/tau-20-955
work_keys_str_mv AT eltajiomar secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes
AT almitwalliabdullah secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes
AT malikfarhan secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes
AT agarwalsamita secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes
AT gogbashianandrew secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes
AT hughesrob secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes
AT vasdevnikhil secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes
AT sharmaanand secondaryneoplasmsoftheurinarybladderclinicalmanagementandoncologicaloutcomes